跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 217 条关于
“Santhera”
全部
217
临床试验
152
药物
19
机构
9
资讯
37
去年
Swissmedic Accepts Santhera's Marketing Application for AGAMREE® in Duchenne Muscular Dystrophy
去年
Santhera's Agamree Receives NICE Recommendation and China NMPA Approval for Duchenne Muscular Dystrophy Treatment
8个月前
Santhera Secures Swiss Approval for AGAMREE as Nxera Expands Asia-Pacific Access for Duchenne Muscular Dystrophy Treatment
12个月前
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE Rollout for Duchenne Muscular Dystrophy
去年
FDA Requests Additional Phase 3 Trial for Santhera's DMD Drug Raxone, Delaying Approval
去年
Agamree Receives Positive Recommendation in Scotland and NICE Guidance in the UK for Duchenne Muscular Dystrophy
2年前
FDA Approves Santhera's Agamree (Vamorolone) for Duchenne Muscular Dystrophy
去年
UK Patients Gain Early Access to Duchenne Muscular Dystrophy Drug Through EAMS
去年
DMD Pipeline Shows Promise with Over 75 Therapies in Development
9个月前
Duchenne Muscular Dystrophy Market Reaches $2.15 Billion as Pipeline Shows Promise with 75+ Active Therapies
第 1 页,共 4 页
上一页
下一页